Haohai Bio-Pharmaceutical's Subsidiary Receives Medical Device Registration Certificate for Injectable Amino Acid Cross-Linked Sodium Hyaluronate Gel

Intelligent Finance APP News: Haohai Biological Technology (688366.SH) announced that its wholly-owned subsidiary, Shanghai Qisheng Biological Preparation Co., Ltd., has recently received the "People's Republic of China Medical Device Registration Certificate" issued by the National Medical Products Administration for the product Sodium Hyaluronate Gel Injectable Crosslinked with Amino Acids. This product is based on the company’s globally pioneering self-developed organic crosslinking technology and is the only hyaluronic acid product in China that uses the natural compound lysine as a crosslinking agent.

In the field of medical aesthetics hyaluronic acid, the company has independently developed and mastered cross-linking technologies such as monophasic cross-linking, low-temperature secondary cross-linking, linear non-particulate cross-linking, and organic cross-linking. This approval marks that the company's fourth-generation hyaluronic acid product, which uses organic cross-linking technology, is now qualified for sales in the Chinese market, further enriching the company’s portfolio of medical aesthetics hyaluronic acid products. The company will leverage this product alongside its first three generations of hyaluronic acid products—“Haiwei,” known for its "shaping" function; “Jiaolan,” focused on "filling"; and “Haimei,” which emphasizes "precise sculpting"—to explore new product combination models based on differentiated functions and pricing strategies. This approach aims to meet the increasingly diversified demands of the medical aesthetics market. Through an extensive sales network, precise and flexible sales strategies, and a professional sales team, the company seeks to increase the overall market share of its hyaluronic acid product series and strengthen its leadership position as a Chinese hyaluronic acid brand.